AMRX - Amneal Pharmaceuticals Inc - Ordinary Shares - Class A
IEX Last Trade
8.65
-0.020 -0.231%
Share volume: 964,238
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$8.67
-0.02
-0.23%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-07 | 2023-03-03 | 2023-05-09 | 2023-08-08 | 2023-11-09 | 2024-03-14 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 4.041 B | 3.874 B | 3.799 B | 3.627 B | 3.701 B | 3.687 B | 3.473 B | 3.456 B | |
| Current Assets | 1.554 B | 1.420 B | 1.412 B | 1.307 B | 1.422 B | 1.456 B | 1.378 B | 1.380 B | |
| Inventories | 533.028 M | 543.858 M | 530.735 M | 529.042 M | 550.558 M | 576.474 M | 581.384 M | 570.653 M | |
| Other Current Assets | 195.785 M | 120.086 M | 48.946 M | 43.501 M | 42.910 M | 52.837 M | 51.712 M | 53.723 M | |
| Short Term Investments | 195.785 M | 120.086 M | 48.946 M | 43.501 M | 42.910 M | 52.837 M | 51.712 M | 53.723 M | |
| Total Receivables | 726.606 M | 659.997 M | 796.910 M | 583.713 M | 713.739 M | 731.157 M | 645.660 M | 704.051 M | |
| Current Cash | 91.979 M | 87.335 M | 25.976 M | 144.674 M | 109.284 M | 86.929 M | 91.542 M | 46.520 M | |
| Total Non-current Assets | 2.488 B | 2.454 B | 2.388 B | 2.319 B | 2.279 B | 2.231 B | 2.095 B | 2.076 B | |
| Property Plant Equipment | 483.625 M | 470.150 M | 469.815 M | 462.606 M | 459.108 M | 451.852 M | 447.574 M | 439.815 M | |
| Other Assets | 143.279 M | 172.730 M | 166.641 M | 148.828 M | 154.810 M | 149.591 M | 114.797 M | 133.279 M | |
| Intangible Assets | 1.204 B | 1.159 B | 1.096 B | 1.055 B | 1.015 B | 982.531 M | 890.423 M | 859.272 M | |
| Goodwill | 600.974 M | 599.504 M | 598.853 M | 599.156 M | 599.206 M | 598.631 M | 598.629 M | 598.549 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 4.041 B | 3.874 B | 3.799 B | 3.627 B | 3.701 B | 3.687 B | 3.473 B | 3.456 B | |
| Total liabilities | 3.761 B | 3.577 B | 3.501 B | 3.332 B | 3.383 B | 3.356 B | 3.453 B | 3.520 B | |
| Total current liabilities | 993.064 M | 817.995 M | 752.800 M | 703.709 M | 777.350 M | 760.601 M | 846.595 M | 834.388 M | |
| Accounts Payable | 0.000 | 0.000 | 165.980 M | 136.922 M | 139.527 M | 177.400 M | 0.000 | 175.325 M | |
| Other liabilities | 89.867 M | 88.554 M | 97.117 M | 52.663 M | 48.405 M | 52.922 M | 41.771 M | 121.452 M | |
| Current long term debt | 118.238 M | 93.497 M | 93.449 M | 133.274 M | 153.624 M | 109.631 M | 215.592 M | 215.965 M | |
| Long term debt | 2.721 B | 2.708 B | 2.692 B | 2.662 B | 2.650 B | 2.642 B | 2.486 B | 2.478 B | |
| Other liabilities | 89.867 M | 88.554 M | 97.117 M | 52.663 M | 48.405 M | 52.922 M | 41.771 M | 121.452 M | |
| Minority interest | -89.451 M | -80.805 M | -89.493 M | -132.219 M | -135.295 M | -139.480 M | 41.523 M | 47.117 M | |
| Total Shareholder equity | 280.327 M | 297.469 M | 298.421 M | 294.414 M | 318.169 M | 330.860 M | 19.781 M | -63.724 M | |
| Common stock | 150.993 M | 151.393 M | 151.498 M | 152.109 M | 153.738 M | 154.219 M | 244.478 M | 307.279 M | |
| Retained earnings | -399.161 M | -401.850 M | -406.183 M | -413.126 M | -401.209 M | -391.527 M | -490.176 M | -581.819 M |